As of 2:30 PM on the 6th, Celltrion is trading at 356,000 KRW, up 0.42% from the previous day. This is a decline of 11.77% compared to December 7. Celltrion is known as a protein and biopharmaceutical manufacturing company.

Today, foreigners have net sold 29,000 shares of Celltrion, and institutions have net sold 30,000 shares, according to provisional data. Over the past five days, individual investors have net bought 194,361 shares, while foreigners and institutions have net bought 162,927 shares and net sold 344,289 shares, respectively.


On January 5, Celltrion was a market topic for its "strength following the disclosure of Phase 2 clinical trial results of the COVID-19 antibody treatment."





[Table] Foreigners and Institutions Net Trading Volume (Unit: shares)

※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing